LifeSci Capital analyst Cory Jubinville, PhD has maintained their bullish stance on LQDA stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors surrounding Liquidia Technologies’ promising developments. The company recently showcased new data at the 2025 American Thoracic Society Conference, highlighting the potential of its lead asset, Yutrepia, a dry powder inhaler for treprostinil. The data from the ASCENT trial, which is the first clinical study of this inhaler in PH-ILD, demonstrated the potential to optimize dosing while maintaining a favorable safety profile.
Cory Jubinville, PhD’s rating is based on the anticipation of Yutrepia’s upcoming PDUFA date, where it is expected to transition from tentative to full approval for both PAH and PH-ILD. The recent findings, along with a positive outlook from a Key Opinion Leader regarding Yutrepia’s efficacy and tolerability, further support the Buy rating. Additionally, the potential market opportunity is underscored by the upcoming loss of exclusivity for a competing product, Tyvaso DPI, which could enhance Yutrepia’s market positioning.
Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Mereo Biopharma Group Plc, and Verve Therapeutics. According to TipRanks, Jubinville, PhD has an average return of -12.8% and a 29.76% success rate on recommended stocks.
In another report released today, Needham also maintained a Buy rating on the stock with a $25.00 price target.